0.83
+0.0059(+0.72%)
Currency In USD
| Previous Close | 0.82 |
| Open | 0.83 |
| Day High | 0.85 |
| Day Low | 0.81 |
| 52-Week High | 1.99 |
| 52-Week Low | 0.45 |
| Volume | 48,760 |
| Average Volume | 325,439 |
| Market Cap | 62.25M |
| PE | -1.29 |
| EPS | -0.64 |
| Moving Average 50 Days | 0.72 |
| Moving Average 200 Days | 1.04 |
| Change | 0.01 |
If you invested $1000 in Cue Biopharma, Inc. (CUE) since IPO date, it would be worth $71.04 as of July 30, 2025 at a share price of $0.826. Whereas If you bought $1000 worth of Cue Biopharma, Inc. (CUE) shares 5 years ago, it would be worth $41.81 as of July 30, 2025 at a share price of $0.826.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
GlobeNewswire Inc.
Jul 16, 2025 12:00 PM GMT
Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients with low CPS (1-19)12-month overall survival of 88
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
GlobeNewswire Inc.
Jul 01, 2025 8:05 PM GMT
ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC12-month landmark survival of 88% and mOS of 32 months BOSTON, July 01, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a no
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
GlobeNewswire Inc.
Jun 24, 2025 8:48 PM GMT
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a cli